Chinese journalist chen ting, zhao yi, shenzhen
An exclusive distribution business, finalized eight years ago, has finally gained prominence in the recent past。
On 8 january 2026, amy (300896. Sz) announced that in china (including macao and hong kong), huons bio pharma co., ltd., korea, was exclusively sold. Injecting type a botulinum toxin products (hereinafter referred to as “huons bp”) obtained a drug registration certificate approved by the national drug control agency, with an approved product specification of 100 u/bottles。
Botoxin is known as a wrinkle-free device in industry. As early as september 2018, amy and hoonsco korea. The distribution agreement for type a botulinum toxin products in china (with huons bp, hereinafter referred to as “huons”) was signed, and the right to this product was subsequently vested in huons bp, with a new distribution agreement signed with huons bp in may 2022。
The above-mentioned cooperation is also part of a project to raise investments of $120 million. At that time, only two bottox products had been approved for listing in the country, namely, the checks and balances produced by the land state institute of biological products and botox, as well as those produced by the united states of america, until the time of the take-up of the testimony by the emeralds, seven of the authorized bottox products had been produced in the country。
Did amy miss the best commercial opportunity in the meantime? What kind of sales strategy has the company developed
On 12 january 2026, in an interview with the newspaper china operator, the ayatollah side stated: “the penetration rate in the chinese botoxin market is still well below that of the mature market and there is wide scope for future growth. The current timing of product approval is at a time when markets are becoming more regulated and consumer awareness is becoming more mature, providing us with a more rational and sustainable window of commercialization. We will rely on established professional channels and brand advantages to move the market forward efficiently.” the company will determine the timing of the sale of type a botulinum toxin products in china on the basis of factors such as the timing of testing of imported drugs and market conditions. In addition, companies will define their marketing strategies by undertaking a comprehensive assessment of r & d costs, market positioning, channels, brand names, and coordination with existing company products。
Two extensions to fund-raising
On 8 january 2026, the imam exclusive product was registered as the seventh authorized botoxin product in the country。
Aimee told journalists that the next step of the company's work, in addition to applying for and passing the inspection of imported medicines as soon as possible, would be to actively promote the commercialization of the product before it was marketed, with a view to achieving sales as soon as possible and creating synergies with the company's existing products。
According to a report published in frost sullivan, botulinum toxin products are the same as those of bouria acids, glue proteins and regenerative materials, the core of which is type a botulinum toxin, whose function is to disrupt the transmission of signals between nerves and muscles in order to relax muscles, reduce muscle sizes and adapt to local wrinkles, lean faces, thin legs, etc. Botulinum toxins, although widely used in the field of medical injection, fall within the category of medically toxic drugs。
Emerald is one of the early companies in the country with botulinum toxin products. As early as september 2018, amy and huons signed an exclusive distribution agreement for type a botoxin products. In accordance with the agreement, huons authorized the import, registration and distribution within the region of china of the a-type botulinum toxin product produced by imam, who was responsible for completing the clinical trials and registration applications for the product in china. Once the product was approved, it was sold by the sole agent of amy in china for a period of 10 years, with a total contract value of $5. 35 million。
According to the emerald book, huons, a leading korean pharmaceutical and medical equipment firm, was founded in 1965 and listed on the korea stock exchange in 2006 and its development of type a botox product, hutox, obtained a product registration certificate in korea in april 2019. In the view of aimee, botulinum toxin has become one of the most widely used medicines for medical beauty, with enormous market space, when only two botulinum toxin products that have been authorized to be listed on the domestic market account for the bulk of the domestic market, but it is difficult to meet the country's huge demand for medical beauty. New entrants therefore face good development opportunities。
In 2020, amy was listed on the entrepreneurship board, and his cooperation with huons was one of the projects - injecting type a botulinum toxin research and development project is considered a “new growth point for corporate business” by emmy. The project is mainly for the clinical testing and registration of type a bottox products injected into china. It is under the responsibility of ayemite. Huons provides all the necessary technical information in his possession. Both sides cooperate in obtaining a drug registration certificate for the product in china. The project construction period is 65 months。
Subsequently, amy and korean partners were further bound. In june 2021, ayatollah announced the use of part of the excess fund to replenish huons bp and purchase 8. 8 per cent of its equity. Upon completion of the transaction, the emerald will hold 25. 4 per cent of the shares of huons bp. Huons bp was originally the botoxin operations unit of huons global until april 2021, when huons global was dismantled。
In may 2022, aimee signed a distribution agreement with huons bp to introduce, by means of r & d registration, type a botulinum toxin products produced by huons bp and to act as the sole and exclusive importer and distributor designated by huons bp in the agreed distribution area (i. E. China, including macao and hong kong)。
Under the above-mentioned agreement, the aimee is required to obtain a licence for the import and sale of the products under the agreement and the import and distribution of the products is subject to the company obtaining a registration of the products in the area of operation. Until july 2024, the registration permit for the use of type a botulinum toxin products for injecting drugs requested by the a-maxer was accepted。
According to the original plan, the date of 31 december 2024 was 31 december 2024 for the idu-type botulinum toxin development project. However, on 16 december 2024, aimee announced the extension of the project until 31 december 2025, as the listing of the product was pending approval by the supervisory authority, which took some time. On 25 december 2025, emmett again announced the extension of the project, adjusted to reach its intended operational status by 31 december 2026。
The market is competitive
The two-time postponement of the fund-raising project has raised concerns in the market about the prospects for the approval of the botoxin products。
Aimee indicated to journalists that injection of type a botoxin is a strictly regulated drug category, that the registration review process is in accordance with the relevant laws and regulations and with the requirements of the national drug control agency, and that there are no delays in approval。
It cannot be overlooked that the number of botoxin products that have been approved in the country has increased from two to seven, starting with the distribution of botoxin products by the americas, and that other enterprises are entering the market。
According to reports issued by the capricorn consultation, the market for type a botulinum toxin injected in our country was about $8. 1 billion in 2023, with a compound increase of nearly 30 per cent over the past five years. Before the approval of the america botulinum toxin product was obtained, a total of 6 items of type a botulinum toxin product were approved for listing, with a total of 10 batches (with different specifications) at a price of $400-2000/50u, of which 5 were imported. Among them, prozac was first listed (2009) and has long been a leader in the chinese market (especially at the high end of the market); the country's production card balance was approved in 2012, with high value for money and greater competitiveness in the middle and lower markets; the lettyon marketed in 2020 has been rapidly rising in recent years, particularly in favour of young consumers, and has gradually gained recognition for its approval in the same year; in 2024, simma and dahirie came to the market with a short-term six-point pattern. In addition, there are a number of established drug companies active in the distribution and introduction of injecting botulinum toxin products through acquisitions, authorizations, etc。
In the face of competition in the market, emmy said to journalists that the company's exclusive distribution of huons bp botulinum toxin products, the future focus mainly on high-middle markets, relying on the company's extensive and deep network of channels and customer trust, and combining existing products to provide more comprehensive and customized treatments for consumers。
In addition, in its bulletin, emmy stressed that the import and sale of type a botulinum toxin products by injection was influenced by factors such as internal and external regulatory policies, the market environment and exchange rate fluctuations. At the same time, there may be a risk of delay, change, suspension or termination in the performance of distribution agreements due to force majeure or other reasons, which in turn may lead to difficulties in obtaining the expected return on the company's prior input。
According to the press, in the first three quarters of 2025, america received approximately 1,865 million yuan, a 21. 49 per cent decrease over the same period; net profits of approximately 1,093 million yuan, a 31. 05 per cent decrease over the same period; net profits from non-net profits, a 36. 2 per cent decrease over the same period; and net cash flows from operating activities, a decline of 30. 12 per cent to approximately 1,073 million yuan over the same period。
